Trademark: 97796895
Word
A2 BIOTHERAPEUTICS
Status
Pending
Status Code
686
Status Date
Tuesday, March 26, 2024
Serial Number
97796895
Mark Type
4000
Filing Date
Wednesday, February 15, 2023
Published for Opposition
Tuesday, March 26, 2024

Trademark Owner History
A2 Biotherapeutics, Inc. - Owner At Publication

Classifications
5 Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
BIOTHERAPEUTICS

Trademark Events
Mar 26, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 26, 2024
Published For Opposition
Mar 6, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 6, 2024
Notification Of Notice Of Publication E-Mailed
Feb 16, 2024
Approved For Pub - Principal Register
Feb 16, 2024
Teas/Email Correspondence Entered
Feb 16, 2024
Correspondence Received In Law Office
Feb 16, 2024
Teas Response To Office Action Received
Nov 17, 2023
Notification Of Priority Action E-Mailed
Nov 17, 2023
Priority Action E-Mailed
Nov 17, 2023
Priority Action Written
Nov 14, 2023
Assigned To Examiner
Mar 6, 2023
New Application Office Supplied Data Entered
Feb 18, 2023
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24